Prevalence Of Protective Tetanus Antibodies And Immunological Response Following Tetanus Toxoid Vaccination Among Men Seeking Medical Circumcision Services In Uganda

Simple item page
dc.contributor.authorMakumbi, Fredrick
dc.contributor.authorByabagambi, John
dc.contributor.authorMuwanika, Richard
dc.contributor.authorKigozi, Godfrey
dc.contributor.authorGray, Ronald
dc.contributor.authorGalukande, Moses
dc.contributor.authorBagaya, Bernard
dc.contributor.authorSsebagala, Darix
dc.contributor.authorKaramagi, Esther
dc.contributor.authorRahimzai, Mirwais
dc.contributor.authorKaggwa, Mugagga
dc.contributor.authorWatya, Stephen
dc.contributor.authorMbonye, Anthony K.
dc.contributor.authorAceng, Jane Ruth
dc.contributor.authorMusinguzi, Joshua
dc.contributor.authorKiggundu, Valerian
dc.contributor.authorNjeuhmeli, Emmanuel
dc.contributor.authorNanteza, Barbara
dc.date.accessioned2021-12-28T16:28:45Z
dc.date.available2021-12-28T16:28:45Z
dc.date.issued2018
dc.description.abstractTetanus infection associated with men who had male circumcision has been reported in East Africa, suggesting a need for tetanus toxoid-containing vaccines (TTCV).To determine the prevalence of tetanus toxoid antibodies following vaccination among men seeking circumcision. We enrolled 620 consenting men who completed a questionnaire and received TTCV at enrollment (day 0) prior to circumcision on day 28. Blood samples were obtained at day 0 from all enrollees and on days 14, 28 and 42 from a random sample of 237 participants. Tetanus toxoid (TT) IgG antibody levels were assayed using EUROIMMUN. Analyses included prevalence of TT antibodies at enrollment and used a mixed effects model to determine the immunological response.Mean age was 21.4 years, 65.2% had knowledge of tetanus, 56.6% knew how tetanus was contracted, 22.8% reported ever receipt of TTCV, and 16.8% had current/recently healed wounds. Insufficient tetanus immunity was 57.1% at enrollment, 7.2% at day 14, 3.8% at day 28, and 0% at day 42. Antibody concentration was 0.44IU/ml (CI 0.35–0.53) on day 0, 3.86IU/ml (CI 3.60–4.11) on day 14, 4.05IU/ml (CI 3.81–4.29) on day 28, and 4.48IU/ml (CI 4.28–4.68) on day 42. TT antibodies increased by 0.24IU/ml (CI 0.23, 0.26) between days 0 and 14 and by 0.023IU/ml (CI 0.015, 0.031) between days 14 and 42 days. Immunological response was poorer in HIV-infected clients and men aged 35+ years.Insufficient immunity was common prior to TTCV, and a protective immunological response was achieved by day 14. Circumcision may safely be provided 14 days after vaccination in HIV-uninfected men aged less than 35 years.en_US
dc.identifier.citationMakumbi, F., Byabagambi, J., Muwanika, R., Kigozi, G., Gray, R., Galukande, M., ... & Nanteza, B. (2018). Prevalence of protective tetanus antibodies and immunological response following tetanus toxoid vaccination among men seeking medical circumcision services in Uganda. PloS one, 13(12), e0209167.https://doi.org/10.1371/journal.pone.0209167en_US
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/944
dc.language.isoenen_US
dc.publisherPloS oneen_US
dc.titlePrevalence Of Protective Tetanus Antibodies And Immunological Response Following Tetanus Toxoid Vaccination Among Men Seeking Medical Circumcision Services In Ugandaen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Prevalence Of Protective Tetanus Antibodies.pdf
Size:
906.56 KB
Format:
Adobe Portable Document Format
Description:
Prevalence Of Protective Tetanus Antibodies And Immunological Response Following Tetanus Toxoid Vaccination Among Men Seeking Medical Circumcision Services In Uganda
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences